GO
Loading...

Glaxo to Buy Biotech Domantis for $450 Million

GlaxoSmithKline agreed to buy privately owned biotech company Domantis, a specialist in developing a new generation of antibody drugs, for 230 million pounds ($452.8 million).

Europe's biggest drugmaker said Domantis would become part of its biopharmaceuticals drug discovery unit while continuing to operate from laboratories in Cambridge, England.

The deal is the latest in a string of recent biotech acquisitions by large pharmaceutical companies eager to boost their pipelines of new medicines.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • United Airlines' Strawberry Fields salad is one of four new premium-cabin entrée salads on North America flights.

    CNBC's Landon Dowdy goes behind the scenes with United Airlines' executive chef as he upgrades the menu for first-class flyers.

  • How the Federal Reserve and consumer sentiment impacts your money, with Larry Glazer, Mayflower Advisors; Christopher Whalen, Kroll Bond Rating Agency; Chris Thornberg, Beacon Economics; "Fast Money" trader Guy Adami; and CNBC's Robert Frank.

  • If you haven't tasted a Rosé lately, it might be time to try again. How do you find the best affordable bottles, and the one that suits your taste? Food and Wine Executive Wine Editor Ray Isle and Becky taste some great affordable Rosé wines. He also explains why Brad and Angelina have entered the business, and why wine growers see green, when they think pink.